Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue Part B Step Therapy Coverage Update |…
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    Medicare Part B Step Therapy — Colony-Stimulating Factors

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs updated Step Therapy requirements for certain nonpreferred Part B medications (colony-stimulating factors) for Florida Blue Medicare Advantage (BlueMedicare) plans and informs prescribers of preferred alternatives and prior authorization expectations.

    Policy Summary
    PayerFlorida Blue
    PolicyMedicare Part B Step Therapy — Colony-Stimulating Factors
    Policy CodePolicy N/A
    Change TypePart B Step Therapy category updated
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionPrescribers must consider preferred alternatives (Fulphila, Udenyca, Nyvepria) before nonpreferred Part B colony-stimulating factors and document medical necessity when requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    One category was updated for the Part B Step Therapy program for BlueMedicare Medicare Advantage plans effective October 1, 2025.

    1

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Part B Step Therapy category updated
    Colony-stimulating factorsDrug class affected
    Preferred listsGuidance provided

    Coverage Criteria

    Coverage contingent on Step Therapy and medical necessity

    Covered when Step Therapy and medical necessity requirements are met.

    Primary Conditions: Coverage for Part B colony-stimulating factors requires that Step Therapy be followed (preferred alternatives considered) and the payer's definition of medical necessity is satisfied.

    Prescribers may need prior authorization for nonpreferred products.

    Step Therapy compliance: Prescriber has tried or documented consideration of preferred alternatives (e.g., Fulphila, Udenyca, Nyvepria) prior to requesting a nonpreferred colony-stimulating factor.

    Per policy, Step Therapy is required for certain nonpreferred Part B medications; prior authorization may apply.

    Medical necessity: Documentation supports medical necessity for the requested agent for the member's Part B indication (for example, chemotherapy-induced neutropenia) and explains why preferred alternatives are not appropriate or have failed.

    Prescribers should document attempts or consideration of preferred alternatives and meet the medical necessity definition when requesting coverage for nonpreferred drugs.

    Denial condition: If Step Therapy requirements and the payer's medical necessity criteria are not met, use of nonpreferred Part B colony-stimulating factors is implied to be not covered.

    Use of nonpreferred Part B medications without meeting Step Therapy or medical necessity requirements may trigger prior authorization denial.

    The policy does not list any explicit clinical exclusions for Part B colony-stimulating factors. Coverage is conditional: benefits are available when Step Therapy requirements are followed and the payer's definition of medical necessity is satisfied. Nonpreferred products may be excluded if the prescriber has not demonstrated compliance with Step Therapy or documented medical necessity.

    If a prescriber requests a nonpreferred Part B colony-stimulating factor without meeting the Step Therapy requirements or without documentation that satisfies medical necessity, the request is implied to be not covered and may be subject to prior authorization denial. Prescribers are encouraged to consider preferred alternatives and to document attempts or rationale when seeking coverage for nonpreferred agents.

    Coding and Product Lists

    Preferred Colony-Stimulating Factor ProductsmixedCovered
    Q5108Fulphila (HCPCS Q-code) listed as preferred product
    Q5111Udenyca (HCPCS Q-code) listed as preferred product
    Q5122Nyvepria (HCPCS Q-code) listed as preferred product
    Non-preferred Colony-Stimulating Factor Products (brand names)mixedNot Covered
    NeulastaNon-preferred product (brand name) listed
    FylnetraNon-preferred product listed
    RolvedonNon-preferred product listed
    StimufendNon-preferred product listed
    RyzneutaNon-preferred product listed
    NypoziNon-preferred product listed
    ZiextenzoNon-preferred product listed
    Non-preferred Colony-Stimulating Factor Products (HCPCS/J-codes)mixedNot Covered
    J2506HCPCS/J-code listed in non-preferred group
    Q5130HCPCS Q-code listed in non-preferred group
    J1449HCPCS/J-code listed in non-preferred group
    Q5127HCPCS Q-code listed in non-preferred group
    J9361HCPCS/J-code listed in non-preferred group
    Q5148HCPCS Q-code listed in non-preferred group
    Q5120HCPCS Q-code listed in non-preferred group

    Provider Actions and Requirements

    Step Therapy

    Step Therapy Required

    Step Therapy is required for certain nonpreferred Part B colony-stimulating factor products. Prescribers should consider and attempt preferred alternatives prior to initiating nonpreferred agents; prior authorization may still be required for preferred products.

    • Preferred alternatives may be subject to prior authorization.
    • Additions to non-preferred products are noted in the policy and must be checked at time of prescribing.
    Documentation Required

    Documentation Expectations

    Prescribers must document attempts or clinical consideration of preferred alternatives when requesting a nonpreferred colony-stimulating factor. Requests for nonpreferred agents must meet the plans definition of medical necessity to be approved.

    • Document trial of preferred product(s) or rationale why preferred products are not appropriate.
    • Include clinical notes, prior medication history, and relevant lab results to support medical necessity.

    Initial Therapy Criteria

    Preferred alternatives recommended

    Preferred-first approach — prescribers should consider listed preferred products before nonpreferred agents.

    Preferred-first requirement: Prescribers are encouraged to consider prescribing preferred colony-stimulating factor products (Fulphila, Udenyca, Nyvepria; HCPCS Q5108, Q5111, Q5122) before selecting nonpreferred agents.

    Prior authorization may apply for preferred or nonpreferred agents.

    Preferred alternatives (examples): Fulphila (Q5108), Udenyca (Q5111), Nyvepria (Q5122) are identified as preferred products and should be considered first.

    Preferred products listed in policy.

    Nonpreferred agents: Nonpreferred colony-stimulating factors include brand and code examples such as Neulasta, Fylnetra, Rolvedon, Stimufend, Ryzneuta, Nypozi, Ziextenzo and codes J2506, Q5130, J1449, Q5127, J9361, Q5148, Q5120; these may require Step Therapy documentation or prior authorization if requested before trial of preferred agents.

    Step Therapy Details

    StepRequirementPreferred alternatives (HCPCS/Codes)Non-preferred products / codesProvider action
    1Prescribers must consider and attempt preferred alternatives before initiating non-preferred Part B colony-stimulating factor products. Step Therapy and the payer's medical necessity requirements must be met.Fulphila (Q5108); Udenyca (Q5111); Nyvepria (Q5122)Neulasta; Fylnetra; Rolvedon; Stimufend; Ryzneuta; Nypozi; Ziextenzo; and related non-preferred codes: J2506; Q5130; J1449; Q5127; J9361; Q5148; Q5120Document attempts or clinical rationale for preferred alternatives; prior authorization may apply for non-preferred agents and coverage is contingent on meeting Step Therapy and medical necessity criteria.

    Biosimilar and Preferred Product Guidance

    Billing Rule

    Preferred products: Fulphila, Udenyca, Nyvepria

    Fulphila, Udenyca, and Nyvepria are identified as the preferred colony-stimulating factor products (Q5108, Q5111, Q5122); other listed agents (e.g., Neulasta, Fylnetra, Rolvedon, Stimufend, Ryzneuta, Nypozi, Ziextenzo and related J/Q codes) are non-preferred and subject to Step Therapy.

    • Preferred: Fulphila (Q5108), Udenyca (Q5111), Nyvepria (Q5122).
    • Non-preferred (examples): Neulasta, Fylnetra, Rolvedon, Stimufend, Ryzneuta, Nypozi, Ziextenzo; associated codes include J2506, Q5130, J1449, Q5127, J9361, Q5148, Q5120.

    Definitions

    Step Therapy (inv-10)
    DefinitionA utilization management program that requires prescribers to try specified preferred alternatives before coverage of certain nonpreferred Part B medications is approved.
    PurposeEncourage use of preferred colony-stimulating factor products when clinically appropriate and limit coverage of nonpreferred agents unless medical necessity is documented.
    Provider requirementPrescribers must consider and document attempts or consideration of preferred alternatives; prior authorization may apply for nonpreferred products.
    ScopeApplies to certain nonpreferred Medicare Part B colony-stimulating factor medications for BlueMedicare plans effective October 1, 2025.
    ExceptionCoverage may be approved for nonpreferred agents when the payer's medical necessity criteria are met and documented.

    Background

    Colony-stimulating factors are agents used to reduce infection risk by stimulating neutrophil production in patients with neutropenia, commonly in the setting of chemotherapy. The Step Therapy program encourages use of preferred agents first when clinically appropriate, with exceptions allowed when medical necessity is documented.

    Policy Summary
    PayerFlorida Blue
    PolicyMedicare Part B Step Therapy — Colony-Stimulating Factors
    Policy CodePolicy N/A
    Change TypePart B Step Therapy category updated
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionPrescribers must consider preferred alternatives (Fulphila, Udenyca, Nyvepria) before nonpreferred Part B colony-stimulating factors and document medical necessity when requesting coverage.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Product ListsProvider Actions and RequirementsInitial Therapy CriteriaStep Therapy DetailsBiosimilar and Preferred Product GuidanceDefinitionsBackground
    Prior Authorization

    Prior Authorization and Denial Risk

    Prior authorization may be required for nonpreferred colony-stimulating factor products. If Step Therapy requirements or the plans medical necessity criteria are not met, the request may be denied.

    • Nonpreferred Part B colony-stimulating factors are subject to denial if Step Therapy or medical necessity is not satisfied.
    • Check members benefit and prior authorization status before administering or billing.
    Note

    Specific Product Guidance

    Examples of preferred and non-preferred colony-stimulating factor products are listed in the policy. Prescribers must consider preferred products (listed below) before non-preferred agents.

    • Preferred products: Fulphila, Udenyca, Nyvepria (HCPCS Q5108, Q5111, Q5122).
    • Non-preferred products include: Neulasta, Fylnetra, Rolvedon, Stimufend, Ryzneuta, Nypozi, Ziextenzo and others (see policy for full HCPCS/NDC listings).

    Additions to non-preferred products are highlighted in the source.